FDA Approves Preservative-free Latanoprost Option
The FDA recently approved the first preservative-free formulation of latanoprost for intraocular pressure reduction in patients with open-angle glaucoma or ocular hypertension. The new drug, Iyuzeh (Thea Pharma), is bottled without the use of benzalkonium (BAK) and other preservatives used in topical ocular preparations, Thea says. According to the company, this will help avoid patients experiencing the moderate to severe signs and symptoms of ocular surface disease associated with such preservatives.
Thea Pharma adds that this product solves a unique challenge of solubilizing and stabilizing latanoprost in that Iyuzeh doesn’t need to be manufactured, distributed or stored at refrigerated temperatures.
In multiple trials across the United States and Europe, Iyuzeh demonstrated consistent IOP-lowering effects and tolerability, Thea says. It lowered IOP by 3 to 8 mmHg in patients with OAG or OHT with a mean baseline IOP of 19 to 24 mmHg, compared to the BAK-preserved Xalatan’s 4 to 8 mmHg.
The recommended dose of Iyuzeh is one drop in the affected eye(s) once daily in the evening. The company says reduction of the IOP begins three to four hours after administration, with the maximum effect achieved after eight to 12 hours, lasting at least 24 hours. The most frequently reported ocular adverse events in the clinical trials included conjunctival hyperemia and eye irritation.
For more information about IYUZEH, visit theapharmainc.com.
For your low-vision patients who may need some more light to read or accomplish near tasks, Eschenbach Optik of America has released a new combination product, the Magno Travel Lamp.
The new lamp is a compact, multi-use lighting tool, the company says. The Magno Travel Lamp doubles as both a desk lamp and a flashlight. The LED lamp weighs less than a pound, and features a rechargeable battery that lasts eight hours for the lamp function and five hours for the flashlight, Eschenbach says.
For the desk-lamp function, the lamp head folds out and extends to a height of 18 inches. Users can choose from three color temperature settings: warm yellow 3,200K, neutral white 4,200K and cool white 6,000K, all of which can be dimmed from 100 percent to 10 percent with the touch of a button. Folding the lamp head in transforms it into a handheld flashlight that measures 10.5 inches.
More information about the Magno Travel Lamp can be found at eschenbach.com.
NovaSight says its CureSight device’s red-blue treatment glasses help treat amblyopic children’s eyes as they stream videos.
CureSight Rolls Out
In 2022, NovaSight announced the FDA clearance of CureSight, its new eye-tracking-based amblyopia treatment device. Designed for at-home use, CureSight helps amblyopic eyes learn to work together while streaming a video of the child’s choice through the red-blue treatment glasses. The device officially began rolling out to the company’s Physician’s Early Adopter Program at the end of 2022. The next phase will occur during the first half of 2023, launching to several hundred physicians who signed up for CureSight’s referral program, says the company. Physicians should note there are three unique CPT codes for CureSight and NovaSight is aiming to reach coverage from the top five U.S. insurance payers in 2023.
For more information, visit nova-sight.com.